Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of LY2409021 on Blood Pressure in T2DM
NCT02091362Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY2409021 with Placebo (2 arms). Primary endpoint: Mean 24-Hour Systolic Blood Pressure at 6 weeks. Started Mar 2014; status: completed.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02091362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091362.